Key Highlights
- Immunome shares traded at $22.16, down 0.72% on the day.
- Phase 1 dosing commenced for 177Lu-IM-3050, noted July 20, 2026.
- 177Lu-IM-3050 is described as an immunotherapy candidate.
- Immunome's market capitalization stands at approximately $2.51 billion.
Immunome Inc. (NASDAQ: IMNM) shares traded at $22.16, down 0.72% on the day, after the company disclosed that Phase 1 dosing has commenced for its immunotherapy candidate 177Lu-IM-3050.
What Happened
The dosing commencement was noted July 20, 2026, according to the disclosed pipeline database.
Market Reaction
Shares traded down 0.72% at $22.16, with Immunome's market capitalization at approximately $2.51 billion, according to the disclosed information.
Outlook
The disclosed information does not include additional detail on the trial design or expected data timeline for 177Lu-IM-3050 beyond the commencement of dosing.
What did Immunome disclose about 177Lu-IM-3050?
Phase 1 dosing has commenced for the immunotherapy candidate, noted July 20, 2026.
What type of candidate is 177Lu-IM-3050?
It is described as an immunotherapy candidate.
What is Immunome's current market capitalization?
Approximately $2.51 billion, according to the disclosed pipeline database.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.